Márquez-González H, De León-Mena S, Yáñez-Gutiérrez L, López-Gallegos D, Camargo-Zetina CO, Ortiz-Vázquez IC, Jiménez-Santos M, Santiago-Hernández JA, Ramírez-Reyes HA, Riera-Kinkel C

Language: English
References: 10
Page: 169-173
PDF size: 211.69 Kb.

ABSTRACT

Aortic coarctation’s (CoA) prevalence is 0.2 in every 1000 live births. Therapeutic options include surgery and, for the last 20 years, interventional cardiology. Objective: To determine the complications of CoA and examine their association with the type of treatment recieved. Methods: Patients that underwent CoA treatment and had follow-up in our center were included. They were included according to treatment in 3 groups: balloon aortoplasty (group 1), stent aortoplasty (group 2) and open surgery (group 3). Patients who suffered from interrupted aortic arch and those who received treatment in other hospitals or presented complications detected in other hospitals were excluded. Data analysis: Descriptive statistics with central mean tendency and dispersion according to distribution, inferential statistics, X-square, ANOVA/Kruskal-Wallis and Kaplan Meier analysis of survival. Results: n =166, age = 18 (range 13-25), 118 male (71%), 48 in group 1, 57 in group 2 and 61 in group 3. The mean follow-up was 15 years. From the analyzed complications, those with statistical significance were: persistent systemic arterial hypertension (group 1, 15%; group 2, 34%; group 3, 41%, p ‹ 0.001) and re-intervention (group 1, 58%; group 2, 11%; group 3, 36%), p = 0.03. Conclusions: The balloon aortoplasty presents greater percentage of reoperation; and aortoplasty stent has fewer complications, but these are manifested in less time.

REFERENCES

1. Jarcho S. Coarctation of the aorta. Am J Cardiol. 1962; 7: 544-547.

2. Jasper A, Keshava SN. Aortic coarctation associated with an absent segment of the proximal right subclavian artery. J Postgrad Med. 2014; 60: 397-399.

3. Kobylińska J, Dworzański W, Cendrowska-Pinkosz M, Dworzańska A, Hermanowicz-Dryka T, Kiszka J et al. Morphological and molecular bases of cardiac development. Postepy Hig Med Dosw (Online). 2013; 67: 950-957.

4. Pinto Júnior VC, Branco KM, Cavalcante RC, Carvalho Junior W, Lima JR, de Freitas SM et al. Epidemiology of congenital heart disease in Brazil. Rev Bras Cir Cardiovasc. 2015; 30: 219-224.

5. Ostovan MA, Kojuri J, Mokhtaryan M, Razazi V, Zolghadrasli A. Procedural outcome and one year follow up of patients undergoing endovascular stenting forcoarctation of aorta: a single center study. J Cardiovasc Thorac Res. 2014; 6: 117-121.

6. Vassilev DI, Rigatelli G, Kaneva-Nencheva A, Levunlieva E, Alexandrov A. Prevention of cerebral embolization by placing a neuroprotection filter before recoarctation stent dilation. JACC Cardiovasc Interv. 2014; 7: e11-e12.

7. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME et al. Infective endocarditis diagnosis, antimicrobial therapy, and management of complications a statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association. Circulation. 2005; 111: e394-e434.

8. Saxena A. Recurrent coarctation: interventional techniques and results. World J Pediatr Congenit Heart Surg. 2015; 6: 257-265.

9. St Louis JD, Harvey BA, Menk JS, O’Brien JE, Kochilas LK. Mortality and operative management for patients undergoing repair of coarctation of the aorta: a retrospective review of the pediatric cardiac care consortium. World J Pediatr Congenit Heart Surg. 2015; 6: 431-437.

10. Canniffe C, Ou P, Walsh K, Bonnet D, Celermajer D. Hypertension after repair of aortic coarctation--a systematic review. Int J Cardiol. 2013; 167: 2456-2461.